According to FUNDER website data,
5 mutual funds hold Protalix shares in the amount of NIS 461.51 thousand
Below is a list of all the funds that hold the stock
The following is a change in the holdings of mutual funds in the Protelix share according to FUNDER-MVF data.
Protalix BotherRepoytics, Inc. (NYSE American and TASE: PLX)
A biopharmaceutical company focusing on the development, production and commercialization of therapeutic recombinant proteins produced using a unique plant-friendly expression and production system called ProCellEx®, announced today that it has signed a worldwide and exclusive licensing agreement with SarcoMed USA Inc. (SarcoMed USA Inc.). For the development of alidornase alpha, or PRX-110, for the treatment of any disease or condition in the respiratory tract in humans, including, inter alia, sarcoidosis, pulmonary fibrosis and related diseases, by inhalation.
Alidornase alpha is a chemically adapted, recombinant form of human deoxyribonuclase I (DNase I) that the company expresses through its unique system of expressing plant cell proteins, and is given through inhalation. U.S. Sarcomed was established in 2017 to investigate whether the innovative DNase I compound may affect chronic pneumonia observed in patients with pulmonary sarcoidosis.
Under the terms of the agreement, Sarcomed will be responsible for identifying and selecting pharmaceutical candidates as specified in the license as well as for the clinical research and development of these candidates. Protalix will be entitled to an initial cash payment of approximately $ 3.5 million, subject to certain conditions, additional payments in accordance with regulatory and commercial milestones as well as tiered royalties in respect of net sales of products marketed under the terms of the license.
The parties further agreed to negotiate clinical and commercial supply agreements for Alidornaz Alpha. As part of the arrangement, the parties agreed to negotiate and sign a supply agreement within 60 days of signing the licensing agreement, US Sarcomed will have the right to terminate the licensing agreement in the event that the parties fail to sign such a supply agreement.
“We are pleased to partner with Sarcomed USA, a private company headed by professionals with extensive experience in pharmaceutical research and development.” Said Dror Bashan, President and CEO of Protelix. “Most patients with pulmonary sarcoidosis do not show symptoms and are unaware of their disease until it is in advanced stages. The treatment alternatives available today vary significantly from patient to patient and, in general, treatments focus on controlling symptoms or improving lung function. There is a market need for treatment that combines symptom control. “We believe that the PRX-110 has the potential to become an exciting therapeutic alternative. We believe this transaction is an additional validity and thickens the line of drug products that can be developed and manufactured using ProCellEx.”
On July 21, 2020, the Food and Drug Administration of the United States (FDA) granted orphan drug alidronase orphan drug status for the treatment of sarcoidosis. A thousand people in the United States.